Interacciones farmacocinéticas

Arazo Garcés, Piedad; Santos Gil, Ignacio de los.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 31(supl.2): 12-19, jun. 2013. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-179604

Documentos relacionados

  1. [Pharmacokinetic interactions].
  2. [Mechanism of action and pharmacokinetics of rilpivirine].
  3. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
  4. [Introduction. Rilpivirine].
  5. Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review.
  6. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
  7. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
  8. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
  9. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
  10. The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.